Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic ...

OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of ...

The French company has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.

A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning ...

Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...

The association between psoriasis severity and CVD may be mediated by systemic inflammation, with a statistically significant ...

MaaT Pharma is focused on developing microbiome-related therapies and its lead candidate is MaaT013, a treatment for acute ...

New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 ...

Pegtarazimod is under clinical development by ReAlta Life Sciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury.

Mesenchymal Stem Cells-Derived Exosomes is under clinical development by AbelZeta and currently in Phase II for Acute Respiratory Distress Syndrome.